2018 Masitinib Drug Analysis: An Oral Tyrosine Kinase Inhibitor Being Developed by AB Science - ResearchAndMarkets.com

DUBLIN--()--The "Drug Analysis: Masitinib" drug pipelines has been added to ResearchAndMarkets.com's offering.

Masitinib (AB Science) is an oral tyrosine kinase inhibitor being developed by AB Science. It targets a number of receptor tyrosine kinases including c-Kit, fibroblast growth factor receptor 3, platelet-derived growth factor receptor alpha/beta, lymphocyte-specific protein tyrosine kinase (Lck), Lck/Yes-related novel protein tyrosine kinase, and focal adhesion kinase.

This makes the drug effective at controlling the survival, differentiation, and degranulation of mast cells, which are involved in oncogenic processes such as angiogenesis, tissue remodeling, and immunomodulation.

Product Profiles

  • masitinib: Prostate cancer
  • masitinib: Colorectal cancer (CRC)
  • masitinib: Asthma
  • masitinib: Pancreatic cancer

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/t7nx98/2018_masitinib?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs